OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+10.41%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$571M
AUM Growth
+$571M
(-4.7%)
Cap. Flow
-$25.5M
Cap. Flow
% of AUM
-4.46%
Top 10 Holdings %
Top 10 Hldgs %
76.16%
Holding
50
New
6
Increased
12
Reduced
12
Closed
11
Top Buys
| 1 |
Immunome
IMNM
|
$8.52M |
| 2 |
Arvinas
ARVN
|
$7.66M |
| 3 |
ESSA Pharma
EPIX
|
$3.96M |
| 4 |
Ginkgo Bioworks
DNA
|
$3.73M |
| 5 |
CRGX
CARGO Therapeutics
CRGX
|
$3.01M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23M |
| 2 |
Applied Therapeutics
APLT
|
$11.2M |
| 3 |
Ocular Therapeutix
OCUL
|
$5.83M |
| 4 |
Cytokinetics
CYTK
|
$3.98M |
| 5 |
Catalyst Pharmaceutical
CPRX
|
$2.24M |
Sector Composition
| 1 | Healthcare | 98.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $134M | 23.43% | 3,990,000 | – | – |
|
2
TG Therapeutics
TGTX
$4.65B
| $68M | 11.9% | 2,260,000 -20,000 | -0.9% | -$602K |
|
3
Codexis
CDXS
$246M
| $42.2M | 7.38% | 8,840,000 +70,000 | +0.8% | +$334K |
|
4
Eton Pharmaceutcials
ETON
$464M
| $38M | 6.65% | 2,852,070 +72,070 | +3% | +$960K |
|
|
5
Ocular Therapeutix
OCUL
$2.12B
| $37.1M | 6.49% | 4,342,500 -682,500 | -14% | -$5.83M |
|
|
6
Arvinas
ARVN
$568M
| $33.6M | 5.89% | 1,625,000 +370,000 | +29% | +$7.66M |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $28M | 4.9% | 500,000 | – | – |
|
|
8
Immunome
IMNM
$828M
| $21.7M | 3.79% | 2,040,000 +802,500 | +65% | +$8.52M |
|
9
Liquidia Corp
LQDA
$2.38B
| $20M | 3.49% | 1,698,142 | – | – |
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $12.8M | 2.24% | 480,000 -42,500 | -8% | -$1.13M |
|
|
11
Ginkgo Bioworks
DNA
$750M
| $11.8M | 2.06% | 1,200,000 +379,798 | +46% | +$3.73M |
|
|
CRGX
12
DELISTED
CARGO Therapeutics
CRGX
| $10.8M | 1.89% | 750,000 +208,563 | +39% | +$3.01M |
|
13
Protara Therapeutics
TARA
$120M
| $9.64M | 1.69% | 1,825,000 +143,846 | +9% | +$760K |
|
14
Trevi Therapeutics
TRVI
$883M
| $9.55M | 1.67% | 2,317,500 -250,490 | -10% | -$1.03M |
|
15
Jasper Therapeutics
JSPR
$45.5M
| $8.55M | 1.5% | 400,000 +46,500 | +13% | +$994K |
|
16
NewAmsterdam Pharma
NAMS
$2.71B
| $8.35M | 1.46% | 325,000 -10,000 | -3% | -$257K |
|
|
SLRN
17
DELISTED
ACELYRIN
SLRN
| $7.17M | 1.26% | 2,235,000 +341,340 | +18% | +$1.1M |
|
18
Nurix Therapeutics
NRIX
$714M
| $7.13M | 1.25% | 378,500 -41,500 | -10% | -$782K |
|
19
Xoma
XOMA
$392M
| $6.57M | 1.15% | 250,000 | – | – |
|
20
Vaxcyte
PCVX
$4B
| $6.14M | 1.07% | 75,000 -10,000 | -12% | -$819K |
|
21
Zentalis Pharmaceuticals
ZNTL
$122M
| $5.36M | 0.94% | 1,767,500 +800,500 | +83% | +$2.43M |
|
22
Biodesix
BDSX
$62.6M
| $5.3M | 0.93% | 3,465,000 -350,000 | -9% | -$536K |
|
23
Nuvalent
NUVL
$5.52B
| $4.58M | 0.8% | 58,500 -5,500 | -9% | -$431K |
|
24
Gossamer Bio
GOSS
$562M
| $4.06M | 0.71% | 4,490,000 +824,990 | +23% | +$746K |
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $4.05M | 0.71% | 105,000 | – | – |
|